

## **Agilent & Theragen Bio to advance bioinformatic solutions for cancer genomic profiling in South Korea**

27 April 2023 | News

**New collaboration combines Agilent's SureSelect Cancer CGP assay and Theragen Bio's localised analysis software**

American firm Agilent Technologies Inc. has announced the recent signing of a Memorandum of Understanding (MoU) with Theragen Bio in South Korea to boost precision oncology through advancing bioinformatic (BI) solutions. As part of the partnership agreement, Agilent and Theragen Bio will combine their respective strengths in cancer genomic profiling (CGP) design, engineering knowledge and software expertise to drive localised analysis capabilities and accelerate treatment decisions.

Agilent's SureSelect Cancer CGP assay uses next generation sequencing (NGS) to transform translational research and clinical trials in oncology through high throughput sequencing of DNA and RNA bases in parallel, while reducing hands-on time to maximize lab efficiency.

For the past three years, Agilent has made significant contributions to improving patient access to therapeutics and treatment in South Korea. To date, it has a strategic partnership with GI Innovation to bring state-of-the-art science and technology in biomarker testing of immune-anticancer drug GI-101. Last year, Agilent received approval from the South Korea Ministry of Food and Drug Safety (MFDS) for its companion diagnostic PD-L1 IHC 22C3 pharmDx on Dako Omnis to detect non-small cell lung cancer.